Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$1.32 - $58.0 $26,303 - $1.16 Million
19,927 New
19,927 $28,000
Q2 2022

Aug 16, 2022

SELL
$1.28 - $2.31 $15,616 - $28,182
-12,200 Closed
0 $0
Q1 2022

May 17, 2022

BUY
$1.82 - $3.5 $22,204 - $42,700
12,200 New
12,200 $28,000
Q3 2021

Nov 16, 2021

SELL
$2.59 - $3.36 $62,867 - $81,557
-24,273 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$3.11 - $4.87 $24,593 - $38,511
7,908 Added 48.32%
24,273 $81,000
Q1 2021

May 18, 2021

BUY
$3.66 - $7.67 $59,895 - $125,519
16,365 New
16,365 $71,000
Q3 2020

Nov 17, 2020

SELL
$2.9 - $4.29 $148,975 - $220,381
-51,371 Closed
0 $0
Q2 2020

Aug 17, 2020

BUY
$1.99 - $3.64 $81,629 - $149,312
41,020 Added 396.29%
51,371 $161,000
Q1 2020

May 15, 2020

BUY
$0.28 - $6.23 $2,898 - $64,486
10,351 New
10,351 $25,000

Others Institutions Holding GNPX

About Genprex, Inc.


  • Ticker GNPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,020,300
  • Market Cap $76.8M
  • Description
  • Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...
More about GNPX
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.